In July, Exact Sciences’ chairman and CEO Kevin Conroy presented a proposal to crosswalk Cologuard from its current G-code to a CPT code.
The panel’s recent meeting was to determine if the colorectal cancer screening test would maintain its $492.72 reimbursement after crosswalking the code.
The advisory panel unanimously voted to maintain Cologuard’s current pricing. The vote was 11 to 0, with one abstention.
“CMS will post a preliminary determination after considering the July meeting comments, today’s panel vote and other written comments. A final determination is expected to be released in the November timeframe and will be effective Jan. 1, 2016,” said Mr. Conroy.
More articles on gastroenterology:
4 GI physicians in the news – Aug. 21, 2015
FDA clears new dietary supplements: 3 points
Memorial Hermann implements EndoSoft software for GI
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
